Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 283

1.

Effectiveness of infliximab after adalimumab failure in Crohn's disease.

Chaparro M, Andreu M, Barreiro-de Acosta M, García-Planella E, Ricart E, Domènech E, Esteve M, Merino O, Nos P, Peñalva M, Gisbert JP.

World J Gastroenterol. 2012 Oct 7;18(37):5219-24. doi: 10.3748/wjg.v18.i37.5219.

2.

Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.

Behm BW, Bickston SJ.

Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006893. doi: 10.1002/14651858.CD006893. Review.

PMID:
18254120
3.

Adalimumab for Crohn's disease after infliximab treatment failure: a systematic review.

Da W, Zhu J, Wang L, Lu Y.

Eur J Gastroenterol Hepatol. 2013 Aug;25(8):885-91. doi: 10.1097/MEG.0b013e32836220ab. Review.

PMID:
23817447
4.

[Frequency and possible reasons for the loss of response to biological therapy in Crohn's disease after a one-year treatment period].

Molnár T, Farkas K, Nyári T, Szepes Z, Nagy F, Kiss T, Wittmann T.

Orv Hetil. 2011 Jun 12;152(24):951-7. doi: 10.1556/OH.2011.29128. Hungarian.

PMID:
21609921
5.

Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.

Van Assche G, Vermeire S, Ballet V, Gabriels F, Noman M, D'Haens G, Claessens C, Humblet E, Vande Casteele N, Gils A, Rutgeerts P.

Gut. 2012 Feb;61(2):229-34. doi: 10.1136/gutjnl-2011-300755. Epub 2011 Sep 23.

PMID:
21948942
6.

Frequency and predictors of loss of response to infliximab or adalimumab in Crohn's disease after one-year treatment period - a single center experience.

Molnár T, Farkas K, Nyári T, Szepes Z, Nagy F, Wittmann T.

J Gastrointestin Liver Dis. 2012 Sep;21(3):265-9.

7.

Efficacy of adalimumab in patients with Crohn's disease and failure to infliximab therapy: a clinical series.

Cordero Ruiz P, Castro Márquez C, Méndez Rufián V, Castro Laria L, Caunedo Álvarez A, Romero Vázquez J, Herrerías Gutiérrez JM.

Rev Esp Enferm Dig. 2011 Jun;103(6):294-8.

8.

Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.

Sprakes MB, Hamlin PJ, Warren L, Greer D, Ford AC.

J Crohns Colitis. 2011 Aug;5(4):324-31. doi: 10.1016/j.crohns.2011.02.007. Epub 2011 Mar 10.

PMID:
21683302
9.

Elective switching from infliximab to adalimumab in stable Crohn's disease.

Hoentjen F, Haarhuis BJ, Drenth JP, de Jong DJ.

Inflamm Bowel Dis. 2013 Mar-Apr;19(4):761-6. doi: 10.1097/MIB.0b013e3182802ae1.

PMID:
23446337
10.

Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study.

Peyrin-Biroulet L, Laclotte C, Bigard MA.

Aliment Pharmacol Ther. 2007 Mar 15;25(6):675-80.

11.

Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.

Zorzi F, Zuzzi S, Onali S, Calabrese E, Condino G, Petruzziello C, Ascolani M, Pallone F, Biancone L.

Aliment Pharmacol Ther. 2012 Jun;35(12):1397-407. doi: 10.1111/j.1365-2036.2012.05100.x. Epub 2012 Apr 22.

12.

Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study.

Doecke JD, Hartnell F, Bampton P, Bell S, Mahy G, Grover Z, Lewindon P, Jones LV, Sewell K, Krishnaprasad K, Prosser R, Marr D, Fischer J, R Thomas G, Tehan JV, Ding NS, Cooke SE, Moss K, Sechi A, De Cruz P, Grafton R, Connor SJ, Lawrance IC, Gearry RB, Andrews JM, Radford-Smith GL; Australian and New Zealand Inflammatory Bowel Disease Consortium.

Aliment Pharmacol Ther. 2017 Feb;45(4):542-552. doi: 10.1111/apt.13880. Epub 2016 Dec 19.

PMID:
27995633
13.

Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review.

Billioud V, Sandborn WJ, Peyrin-Biroulet L.

Am J Gastroenterol. 2011 Apr;106(4):674-84. doi: 10.1038/ajg.2011.60. Epub 2011 Mar 15. Review.

PMID:
21407178
14.

Evaluation of adalimumab therapy in multidisciplinary strategy for perianal Crohn's disease patients with infliximab failure.

Echarri A, Castro J, Barreiro M, Carpio D, Pereira S, Lorenzo A.

J Crohns Colitis. 2010 Dec;4(6):654-60. doi: 10.1016/j.crohns.2010.07.012. Epub 2010 Sep 17.

PMID:
21122576
15.

Similar response to adalimumab in patients with active Crohn's disease either naive to biologic agents or with prior loss of response or intolerance to infliximab.

Triantafillidis JK, Mantzaris G, Karagiannis J, Papavasilliou E, Papatheodoridis G, Fouskas J, Malgarinos G, Gikas A, Papamichael K, Mathou N, Symboulakis E, Karamanolis D.

Rev Med Chir Soc Med Nat Iasi. 2010 Jan-Mar;114(1):85-90.

PMID:
20509281
16.

Comparative effectiveness of infliximab and adalimumab for Crohn's disease.

Osterman MT, Haynes K, Delzell E, Zhang J, Bewtra M, Brensinger C, Chen L, Xie F, Curtis JR, Lewis JD.

Clin Gastroenterol Hepatol. 2014 May;12(5):811-817.e3. doi: 10.1016/j.cgh.2013.06.010. Epub 2013 Jun 28.

17.

Effects of infliximab retreatment after consecutive discontinuation of infliximab and adalimumab in refractory Crohn's disease.

Brandse JF, Peters CP, Gecse KB, Eshuis EJ, Jansen JM, Tuynman HA, Löwenberg M, Ponsioen CY, van den Brink GR, DʼHaens GR; North Holland GUT Club.

Inflamm Bowel Dis. 2014 Feb;20(2):251-8. doi: 10.1097/01.MIB.0000438248.14218.1d.

PMID:
24378599
18.

Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland.

Russo EA, Iacucci M, Lindsay JO, Campbell S, Hart A, Hamlin J, Orchard T, Arebi N, Nightingale J, Jacyna MR, Gabe SM, O'Connor M, Harris AW, O'Morain C, Ghosh S.

Eur J Gastroenterol Hepatol. 2010 Mar;22(3):334-9. doi: 10.1097/MEG.0b013e32832b20d4.

PMID:
19528808
19.

Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study.

Seiderer J, Brand S, Dambacher J, Pfennig S, Jürgens M, Göke B, Ochsenkühn T.

Aliment Pharmacol Ther. 2007 Apr 1;25(7):787-96.

20.

Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease.

Choi GK, Collins SD, Greer DP, Warren L, Dowson G, Clark T, Hamlin PJ, Ford AC.

J Crohns Colitis. 2014 May;8(5):375-83. doi: 10.1016/j.crohns.2013.09.017. Epub 2013 Oct 12.

PMID:
24129316

Supplemental Content

Support Center